All In MedTech

Device Trial Radar · NCT04217837

Treatment of Major Depressive Disorder in the UK Using TMS Therapy

Neurostar Transcranial Magnetic Stimulation (TMS) Advanced Therapy System: Data Management, Analysis, and Reporting Format for Clinical Treatment Utilization and Outcomes in the UK

Last checked: Nov 19, 2026Latest source record: Oct 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 2020

Primary completion

Feb 2022

Study completion Feb 2022

Sponsor

Lead sponsor
NeuroneticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 3, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The major objective of this observational study is to describe clinical outcomes of patients in the UK receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.

Conditions

  • Major Depressive Disorder

Interventions

  • Transcranial Magnetic StimulatorDevice

    Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Global Impression - Severity ScaleTime frame: Baseline, 6 weeks, 3, 6, 9, and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St Pancras Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.